Last reviewed · How we verify

Loprinone (OLPRINONE)

FDA-approved active Small molecule ✓ Verified May 2026 Quality 24/100

Loprinone (generic name: OLPRINONE) is a olprinone drug. It is currently FDA-approved for Acute heart failure.

Loprinone is a small molecule with synonyms including LOPRINONE, OLPRINONA, and OLPRINONE.

At a glance

Generic nameOLPRINONE
Drug classolprinone
TargetPhosphodiesterase 3
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Loprinone

What is Loprinone?

Loprinone (OLPRINONE) is a olprinone drug, indicated for Acute heart failure.

What is Loprinone used for?

Loprinone is indicated for Acute heart failure.

What is the generic name of Loprinone?

OLPRINONE is the generic (nonproprietary) name of Loprinone.

What drug class is Loprinone in?

Loprinone belongs to the olprinone class. See all olprinone drugs at /class/olprinone.

What development phase is Loprinone in?

Loprinone is FDA-approved (marketed).

What does Loprinone target?

Loprinone targets Phosphodiesterase 3 and is a olprinone.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing